Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium

Oren Pasvolsky; Danai Dima; Lei Feng; Wenli Dong; Tiffany Richards; James A. Davis; Aimaz Afrough; Mariola Vazquez-Martinez; Aishwarya Sannareddy; Utkarsh Goel; Rahul Banerjee; Jack Khouri; Frances Cervoni; Mahmoud R. Gaballa; Alex Lieberman-Cribbin; Masooma Shifa Rana; Kelley Julian; Christopher J. Ferreri; Leyla Shune; Shaun DeJarnette; Evguenia Bhurtel; Sandra Susanibar Adaniya; Andrew Portuguese; Hitomi Hosoya; Lekha Mikkilineni; Gurbakhash Kaur; Adriana Rossi; Megan M. Herr; Daniel Schrum; Chenyu Lin; Shahzad Raza; Yi Lin; Shonali Midha; Nadeem Omar; Shebli Atarsh; Joseph McGuirk; Douglas Sborov; Peter Voorhees; Faiz Anwer; Melissa Alsina; Ciara Freeman; Alfred L. Garfall; Beatrice M. Razzo; Surbhi Sidana; Andrew J. Cowan; Larry D. Anderson; Doris K. Hansen; Shambavi Richard; Krina K. Patel; Hans C. Lee; Ariel Grajales-Cruz

doi:10.1038/s41408-025-01297-7

Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium

Oren Pasvolsky^*, Danai Dima, Lei Feng, Wenli Dong, Tiffany Richards, James A. Davis, Aimaz Afrough, Mariola Vazquez-Martinez, Aishwarya Sannareddy, Utkarsh Goel, Rahul Banerjee, Jack Khouri, Frances Cervoni, Mahmoud R. Gaballa, Alex Lieberman-Cribbin, Masooma Shifa Rana, Kelley Julian, Christopher J. Ferreri, Leyla Shune, Shaun DeJarnetteEvguenia Bhurtel, Sandra Susanibar Adaniya, Andrew Portuguese, Hitomi Hosoya, Lekha Mikkilineni, Gurbakhash Kaur, Adriana Rossi, Megan M. Herr, Daniel Schrum, Chenyu Lin, Shahzad Raza, Yi Lin, Shonali Midha, Nadeem Omar, Shebli Atarsh, Joseph McGuirk, Douglas Sborov, Peter Voorhees, Faiz Anwer, Melissa Alsina, Ciara Freeman, Alfred L. Garfall, Beatrice M. Razzo, Surbhi Sidana, Andrew J. Cowan, Larry D. Anderson, Doris K. Hansen, Shambavi Richard, Krina K. Patel, Hans C. Lee^*, Ariel Grajales-Cruz

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Teclistamab, a BCMA-directed bispecific antibody, received regulatory approval for relapsed/refractory multiple myeloma (RRMM) based on the MajesTEC-1 study. Despite the fact that myeloma is primarily a cancer of elderly adults, only 15% of MajesTEC-1 participants (n = 24) were ≥75 years old. In this multicenter retrospective study, we report real-world outcomes of a large cohort of older RRMM patients treated with teclistamab. Of 385 analyzed patients, 83 (22%) were in the older group (age ≥75) and 302 (78%) in the younger group (age <75). Compared to the younger group, the older group had less adverse baseline disease characteristics, including a lower incidence of high-risk cytogenetics (44.6% vs. 57.9%, p = 0.03) and extramedullary disease (22% vs. 40%, p = 0.02). There were no significant differences in rates of any-grade CRS (52% vs. 59%, p = 0.27), any-grade ICANS (19% vs. 13%, p = 0.12), and overall response rate (62% vs. 53%, p = 0.17) between the older and younger groups. In multivariable analysis, age was not significantly associated with survival outcomes. Our findings suggest that teclistamab is safe and efficacious in well-selected patients ≥75 years old, and advanced age alone should not preclude teclistamab administration.

Original language	English
Article number	92
Journal	Blood Cancer Journal
Volume	15
Issue number	1
DOIs	https://doi.org/10.1038/s41408-025-01297-7
State	Published - Dec 2025
Externally published	Yes

Funding

Funders	Funder number
Goff-Street Foundation
Cancer Center Support
Pentecost Family Myeloma Research Center
Baer Family Fund
National Cancer Institute	P30 CA016672, R01CA281756-01A1

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41408-025-01297-7

Cite this

Pasvolsky, O., Dima, D., Feng, L., Dong, W., Richards, T., Davis, J. A., Afrough, A., Vazquez-Martinez, M., Sannareddy, A., Goel, U., Banerjee, R., Khouri, J., Cervoni, F., Gaballa, M. R., Lieberman-Cribbin, A., Rana, M. S., Julian, K., Ferreri, C. J., Shune, L., ... Grajales-Cruz, A. (2025). Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium. Blood Cancer Journal, 15(1), Article 92. https://doi.org/10.1038/s41408-025-01297-7

@article{7bb5255762564d238308eb5bb4241530,

title = "Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium",

abstract = "Teclistamab, a BCMA-directed bispecific antibody, received regulatory approval for relapsed/refractory multiple myeloma (RRMM) based on the MajesTEC-1 study. Despite the fact that myeloma is primarily a cancer of elderly adults, only 15\% of MajesTEC-1 participants (n = 24) were ≥75 years old. In this multicenter retrospective study, we report real-world outcomes of a large cohort of older RRMM patients treated with teclistamab. Of 385 analyzed patients, 83 (22\%) were in the older group (age ≥75) and 302 (78\%) in the younger group (age <75). Compared to the younger group, the older group had less adverse baseline disease characteristics, including a lower incidence of high-risk cytogenetics (44.6\% vs. 57.9\%, p = 0.03) and extramedullary disease (22\% vs. 40\%, p = 0.02). There were no significant differences in rates of any-grade CRS (52\% vs. 59\%, p = 0.27), any-grade ICANS (19\% vs. 13\%, p = 0.12), and overall response rate (62\% vs. 53\%, p = 0.17) between the older and younger groups. In multivariable analysis, age was not significantly associated with survival outcomes. Our findings suggest that teclistamab is safe and efficacious in well-selected patients ≥75 years old, and advanced age alone should not preclude teclistamab administration.",

author = "Oren Pasvolsky and Danai Dima and Lei Feng and Wenli Dong and Tiffany Richards and Davis, \{James A.\} and Aimaz Afrough and Mariola Vazquez-Martinez and Aishwarya Sannareddy and Utkarsh Goel and Rahul Banerjee and Jack Khouri and Frances Cervoni and Gaballa, \{Mahmoud R.\} and Alex Lieberman-Cribbin and Rana, \{Masooma Shifa\} and Kelley Julian and Ferreri, \{Christopher J.\} and Leyla Shune and Shaun DeJarnette and Evguenia Bhurtel and \{Susanibar Adaniya\}, Sandra and Andrew Portuguese and Hitomi Hosoya and Lekha Mikkilineni and Gurbakhash Kaur and Adriana Rossi and Herr, \{Megan M.\} and Daniel Schrum and Chenyu Lin and Shahzad Raza and Yi Lin and Shonali Midha and Nadeem Omar and Shebli Atarsh and Joseph McGuirk and Douglas Sborov and Peter Voorhees and Faiz Anwer and Melissa Alsina and Ciara Freeman and Garfall, \{Alfred L.\} and Razzo, \{Beatrice M.\} and Surbhi Sidana and Cowan, \{Andrew J.\} and Anderson, \{Larry D.\} and Hansen, \{Doris K.\} and Shambavi Richard and Patel, \{Krina K.\} and Lee, \{Hans C.\} and Ariel Grajales-Cruz",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2025.",

year = "2025",

month = dec,

doi = "10.1038/s41408-025-01297-7",

language = "אנגלית",

volume = "15",

journal = "Blood Cancer Journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "1",

}

Pasvolsky, O, Dima, D, Feng, L, Dong, W, Richards, T, Davis, JA, Afrough, A, Vazquez-Martinez, M, Sannareddy, A, Goel, U, Banerjee, R, Khouri, J, Cervoni, F, Gaballa, MR, Lieberman-Cribbin, A, Rana, MS, Julian, K, Ferreri, CJ, Shune, L, DeJarnette, S, Bhurtel, E, Susanibar Adaniya, S, Portuguese, A, Hosoya, H, Mikkilineni, L, Kaur, G, Rossi, A, Herr, MM, Schrum, D, Lin, C, Raza, S, Lin, Y, Midha, S, Omar, N, Atarsh, S, McGuirk, J, Sborov, D, Voorhees, P, Anwer, F, Alsina, M, Freeman, C, Garfall, AL, Razzo, BM, Sidana, S, Cowan, AJ, Anderson, LD, Hansen, DK, Richard, S, Patel, KK, Lee, HC & Grajales-Cruz, A 2025, 'Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium', Blood Cancer Journal, vol. 15, no. 1, 92. https://doi.org/10.1038/s41408-025-01297-7

TY - JOUR

T1 - Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab

T2 - a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium

AU - Pasvolsky, Oren

AU - Dima, Danai

AU - Feng, Lei

AU - Dong, Wenli

AU - Richards, Tiffany

AU - Davis, James A.

AU - Afrough, Aimaz

AU - Vazquez-Martinez, Mariola

AU - Sannareddy, Aishwarya

AU - Goel, Utkarsh

AU - Banerjee, Rahul

AU - Khouri, Jack

AU - Cervoni, Frances

AU - Gaballa, Mahmoud R.

AU - Lieberman-Cribbin, Alex

AU - Rana, Masooma Shifa

AU - Julian, Kelley

AU - Ferreri, Christopher J.

AU - Shune, Leyla

AU - DeJarnette, Shaun

AU - Bhurtel, Evguenia

AU - Susanibar Adaniya, Sandra

AU - Portuguese, Andrew

AU - Hosoya, Hitomi

AU - Mikkilineni, Lekha

AU - Kaur, Gurbakhash

AU - Rossi, Adriana

AU - Herr, Megan M.

AU - Schrum, Daniel

AU - Lin, Chenyu

AU - Raza, Shahzad

AU - Lin, Yi

AU - Midha, Shonali

AU - Omar, Nadeem

AU - Atarsh, Shebli

AU - McGuirk, Joseph

AU - Sborov, Douglas

AU - Voorhees, Peter

AU - Anwer, Faiz

AU - Alsina, Melissa

AU - Freeman, Ciara

AU - Garfall, Alfred L.

AU - Razzo, Beatrice M.

AU - Sidana, Surbhi

AU - Cowan, Andrew J.

AU - Anderson, Larry D.

AU - Hansen, Doris K.

AU - Richard, Shambavi

AU - Patel, Krina K.

AU - Lee, Hans C.

AU - Grajales-Cruz, Ariel

PY - 2025/12

Y1 - 2025/12

N2 - Teclistamab, a BCMA-directed bispecific antibody, received regulatory approval for relapsed/refractory multiple myeloma (RRMM) based on the MajesTEC-1 study. Despite the fact that myeloma is primarily a cancer of elderly adults, only 15% of MajesTEC-1 participants (n = 24) were ≥75 years old. In this multicenter retrospective study, we report real-world outcomes of a large cohort of older RRMM patients treated with teclistamab. Of 385 analyzed patients, 83 (22%) were in the older group (age ≥75) and 302 (78%) in the younger group (age <75). Compared to the younger group, the older group had less adverse baseline disease characteristics, including a lower incidence of high-risk cytogenetics (44.6% vs. 57.9%, p = 0.03) and extramedullary disease (22% vs. 40%, p = 0.02). There were no significant differences in rates of any-grade CRS (52% vs. 59%, p = 0.27), any-grade ICANS (19% vs. 13%, p = 0.12), and overall response rate (62% vs. 53%, p = 0.17) between the older and younger groups. In multivariable analysis, age was not significantly associated with survival outcomes. Our findings suggest that teclistamab is safe and efficacious in well-selected patients ≥75 years old, and advanced age alone should not preclude teclistamab administration.

AB - Teclistamab, a BCMA-directed bispecific antibody, received regulatory approval for relapsed/refractory multiple myeloma (RRMM) based on the MajesTEC-1 study. Despite the fact that myeloma is primarily a cancer of elderly adults, only 15% of MajesTEC-1 participants (n = 24) were ≥75 years old. In this multicenter retrospective study, we report real-world outcomes of a large cohort of older RRMM patients treated with teclistamab. Of 385 analyzed patients, 83 (22%) were in the older group (age ≥75) and 302 (78%) in the younger group (age <75). Compared to the younger group, the older group had less adverse baseline disease characteristics, including a lower incidence of high-risk cytogenetics (44.6% vs. 57.9%, p = 0.03) and extramedullary disease (22% vs. 40%, p = 0.02). There were no significant differences in rates of any-grade CRS (52% vs. 59%, p = 0.27), any-grade ICANS (19% vs. 13%, p = 0.12), and overall response rate (62% vs. 53%, p = 0.17) between the older and younger groups. In multivariable analysis, age was not significantly associated with survival outcomes. Our findings suggest that teclistamab is safe and efficacious in well-selected patients ≥75 years old, and advanced age alone should not preclude teclistamab administration.

UR - http://www.scopus.com/inward/record.url?scp=105004584303&partnerID=8YFLogxK

U2 - 10.1038/s41408-025-01297-7

DO - 10.1038/s41408-025-01297-7

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 40346049

AN - SCOPUS:105004584303

SN - 2044-5385

VL - 15

JO - Blood Cancer Journal

JF - Blood Cancer Journal

IS - 1

M1 - 92

ER -

Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium

Abstract

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this